| Literature DB >> 22110329 |
Abstract
The nervous system and the skin develop next to each other in the embryo and remain intimately interconnected and interactive throughout life. The nervous system can influence skin conditions through psychoneuroimmunoendocrine mechanisms and through behaviors. Understanding the pathophysiology aids in selection of treatment plans for correcting the negative effects of the psyche on specific skin conditions. Medication options include standard psychotropic medications and alternative herbs and supplements. Other options include biofeedback, cognitive-behavioral methods, hypnosis, meditation, progressive relaxation, the placebo effect, and suggestion. When simple measures fail, combining medications with other therapeutic options may produce better results. Skin conditions that have strong psychophysiologic aspects may respond well to techniques such as biofeedback, cognitive-behavioral methods, hypnosis, meditation, or progressive relaxation that help to counteract stress. Treatment of primary psychiatric disorders that negatively influence skin conditions often results in improvement of those skin conditions. Abnormal conditions of the skin, hair, and nails can also influence the psyche negatively. Treatment of secondary psychiatric disorders such as anxiety or depression that are triggered or exacerbated by the appearance of these skin conditions or the associated discomfort may also be required.Entities:
Keywords: alternative; non-drug; psychocutaneous; psychodermatology; psychosomatic; skin disorders; standard; treatment
Year: 2010 PMID: 22110329 PMCID: PMC3218765 DOI: 10.2147/prbm.s7072
Source DB: PubMed Journal: Psychol Res Behav Manag ISSN: 1179-1578
Antidepressants used in dermatologic conditions
| Category | Agent | Dosage | Side effects | Cautions |
|---|---|---|---|---|
| SSRI | Citalopram (Celexa®) | 20–40 mg daily | Sedation | SSRIs slow |
| Escitalopram (Lexapro®) | 10 mg daily | onset of effect | ||
| Fluoxetine (Prozac®) | 20–80 mg daily | Insomnia | Taper off slowly | |
| Fluvoxamine (Luvox®) | 25–150 mg bid | GI symptoms | Multiple drug | |
| Paroxetine (Paxil®) | 20–50 mg daily | Sedation | Interactions | |
| Sertraline (Zoloft®) | 25–200 mg daily | GI symptoms | ||
| Venlafaxine (Effexor®) | 25–75 mg tid | |||
| Tricyclic | Amitriptyline (Elavil®) | 25–50 mg daily | Sedation, dry mouth | Tricyclics |
| Clomipramine (Anafranil®) | 25–250 mg daily | Sedation, dry mouth | Risk of seizures | |
| Doxepin (Sinequan®) | 25–300 mg daily | Sedation | ||
| Imipramine (Tofranil®) | 25–300 mg daily | Orthostatic hypotension | Heart dysconduction | |
| Nortriptyline (Pamelor®) | 25–150 mg daily | Dry mouth | ||
| Protryptyline (Vivactil®) | 5–20 mg tid | Dry mouth | ||
| Trimipramine (Surmontil®) | 5–50 mg tid | Sedation | ||
| NE/DUI | Bupropion (Welbutrin®) | 75–150 mg bid | ||
| Herbs | St. John’s wort | 300–1200 mg daily | Photosensitivity | Drug interactions |
| Supplement | SAMe | 200–800 mg bid | ||
| Non-drug | Exercise | Daily | ||
| Hypnosis | Daily |
Abbreviations: bid, twice daily; GI, gastrointestinal; SSRI, selective serotonin reuptake inhibitor; NE/DUI, norepinephrine and dopamine reuptake inhibitor; SAMe, S-adenosul-L-methionine; tid, three times daily.
Antipsychotics and anticonvulsants used in dermatologic conditions
| Category | Agent | Dosage | Side effects | Cautions |
|---|---|---|---|---|
| Typical | Haloperidol (Haldol®) | 5–20 mg daily acutely | Tardive dyskinesia | Mild sedation |
| Pimozide (Orap®) | 0.5–10 mg daily acutely | Tardive dyskinesia | ||
| Atypical | Olanzapine (Zyprexa®) | 2.5–10 mg daily | Weight gain | Diabetes |
| GABA | Gabapentin (Neurontin®) | 100–600 mg tid | ||
Abbreviations: bid, twice daily; GABA, gamma amino butyric acid; tid, three times daily.
Anxiolytics used in dermatologic conditions
| Category | Agent | Dosage | Side effects | Cautions |
|---|---|---|---|---|
| Benzodiazepines | Alazopram (Xanax) | 0.25–0.5 mg tid | Short-acting sedation | Use caution |
| Lorazepam (Ativan) | 1 mg bid–tid | Short-acting sedation | Driving | |
| Diazepam (Valium) | 2–10 mg bid–qid | Long-acting sedation | With each | |
| Azaperone | Buspirone (Buspar) | 5–30 mg bid | Very slow acting | |
| Herbs | Magnolia bark | 250–750 mg daily | ||
| Passion flower | 0.5 1 ml fluid extract | |||
| Non-drug | Biofeedback | Daily and prn | ||
| Cognitive-behavioral | Daily | |||
| Hypnosis | Daily and prn | Avoid use driving | ||
| Meditation | Daily and prn | Avoid use driving | ||
| Placebo | Prn | |||
| Suggestion | Prn | |||
| Yoga | Daily and prn |
Abbreviations: bid, twice daily; Prn, per required need; tid, three times daily.
Sedatives used in dermatologic conditions
| Category | Agent | Dosage | Side effects | Cautions |
|---|---|---|---|---|
| Antihistamines | Certirizine (Zyrtec®) | 10 mg daily | Sedative | Use caution driving |
| Diphenhydramine (Benadryl®) | 25–50 mg tid–qid | Sedative | With each | |
| Doxepin (Sinequan®) | 25–100 mg tid | Sedative | ||
| Hydroxyzine (Atarax®) | 25–100 mg tid | Sedative | ||
| Levocetrizine (Xyzal®) | 5 mg daily | Mild sedative | ||
| Promethazine (Phenergan®) | 25–100 mg tid–qid | Sedative | ||
| Herbs | Valerian | 300–900 mg daily HS | ||
| Supplements | Melatonin | 3 mg HS | ||
| Nondrug | Hypnosis | HS | Avoid use driving | |
| Progressive relaxation | HS |
Abbreviations: HS, at bedtime; qid, four times daily; tid, three times daily.
Antipruritics used in dermatologic conditions
| Category | Agent | Dosage | Side effects | Cautions |
|---|---|---|---|---|
| Herbs | Capsaicin | Topical qid | Burning sensation | Avoid eyes |
| Camphor | Topical prn | |||
| Menthol | Topical prn | |||
| Nondrug | Hypnosis | Daily and prn | Avoid use driving |
Abbreviations: Prn, per required need; qid, four times daily.